VarmX

About VarmX

VarmX is focused on developing a breakthrough, swift-acting, and convenient universal bypassing agent to restore blood coagulation in patients taking Factor Xa Direct Oral Anticoagulants (FXa-DOACs). Their mission is to stop severe bleeding and eliminate bleeding risks during surgery for these patients.

Products & Services

VMX-C001:A lead asset aimed at transforming the treatment of bleeding in patients taking Factor Xa DOACs.

Specialties

Blood coagulation restoration Factor Xa Direct Oral Anticoagulants (FXa-DOACs) treatment Severe bleeding prevention

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B2 T: - FT: Series B2	A: 33630000 MR: - FA: €30 million FAN: 33630000	D: 2023-05-25 FD: 2023-05-25	9 investors

Series B2 Latest

2023-05-25

$33.6M

9 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

P

Pieter Reitsma

Special Advisor and Founder

J

John Glasspool

Chief Executive Officer

J

Jan Öhrström

Chairman

P

Paul Roos

Chief Financial Officer

G

Ged Short

Chief Medical Officer

M

Martijn Negen

Chief Operating Officer

View 17 more team members with Pro

Unlock Full Team Directory

Recent News

VarmX Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised